Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 154 participants.
Also called NCT02502981
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 154 participants
- Registry
-
NCT02502981
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Unknown status
Technical summary
Registry record NCT02502981. Allocation not applicable; no masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2018-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD
- Acronym
- SPIRO-CKD
- Condition
- Renal Insufficiency, Chronic
- Condition
- Cardio-Renal Syndrome
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Chlortalidone
- Lead sponsor
- University Hospital Birmingham
- Collaborator
- Royal Free Hospital NHS Foundation Trust
- Collaborator
- University of Edinburgh
- Collaborator
- University of Cambridge
Record details
- Record id
cardio:ct-nct02502981- Content hash
a0c9904acb0291ad93de172d35d00363b2bd9356fb96d77e3ce9dc9fe2c23f44